Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Amendment to LTIP

23 Feb 2021 07:00

RNS Number : 9555P
Intercede Group PLC
23 February 2021
 

23 February 2021

Intercede Group plc

 

("Intercede" or the "Company")

 

Amendment to LTIP

 

 

Following the successful early retirement of the Company's Loan Notes announced on 4 and 16 February 2021, Intercede's Remuneration Committee has determined the following amendments to the existing Intercede Group plc Long Term Incentive Plan (the "LTIP"), as previously announced on 22 October 2018:

 

Revised Performance Criteria

 

· Tranche 1 has been achieved (previously subject to the achievement of an average share price of 69p for a period of 30 consecutive trading days up to and ending 19 October 2021); and

 

· Tranches 2 and 3 will now be triggered subject to the achievement of an average share price of 69p and 119p respectively for a period of 30 consecutive trading days up to and ending 19 October 2021 (previously 119p and 169p respectively).

 

Dependent on the Performance Criteria above being achieved, the number of Options that will vest and become exercisable at an exercise price of 27p (being the closing mid-market price of an Ordinary Share on 18 October 2018, when the LTIP was implemented) from 19 October 2021 to 18 October 2028 is as follows:

Director

Tranche 1

Tranche 2

Tranche 3

Klaas van der Leest

500,000 Options

250,000 Options

250,000 Options

Andrew Walker

350,000 Options

150,000 Options

150,000 Options

 

Chuck Pol, Remuneration Committee Chairman, said:

 

"The LTIP was put in place following the appointment of Klaas van der Leest on 10 April 2018 to incentivise the management team to deliver a performance that would enable the Company to address its Convertible Loan Notes totalling £5.0m when they matured on 29 December 2021.

 

The successful execution of a turnaround plan has enabled Intercede to return to profit and to increase gross cash balances from £2.3m as at 31 March 2018 to £8.1m as at 30 September 2020 during a time when trading conditions have not been favourable.

 

The Remuneration Committee considers the early retirement of the Loan Notes to represent a significant achievement, particularly given that 12 out of 13 loan note holders elected to convert their Loan Notes into shares."

 

 

 

ENQUIRIES

 

Intercede Group plc

Tel. +44 (0)1455 558111

Klaas van der Leest, Chief Executive

Andrew Walker, Finance Director

finnCap

Tel. + 44 (0)20 7220 0500

Stuart Andrews / Simon Hicks, Corporate Finance

Tim Redfern / Charlotte Sutcliffe, ECM

 

About Intercede

 

Intercede is a cybersecurity company specialising in digital identities, credential management and secure mobility.

 

Headquartered in the UK, with offices in the US, we believe in a connected world in which people and technology are free to exchange information securely, and complex insecure passwords become a thing of the past.

 

Our vision is to make the highest levels of cybersecurity available to all organisations, solving complexity issues by simplifying the management of digital credentials, securely and at scale.

 

We have been delivering trusted solutions to high profile customers for over 20 years. Our team of experts has deployed millions of identities to governments, most of the largest aerospace and defence corporations, and major financial services and healthcare organizations, as well as leading telecommunications, cloud services and information technology firms, providing industry-leading employee and customer credential management systems.

 

For more information visit: www.intercede.com

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBRGDDISDDGBD
Date   Source Headline
17th Dec 201810:19 amRNSBoard Change
26th Nov 20187:00 amRNSHalf-year Report
22nd Oct 20187:00 amRNSGrant of Options
4th Oct 20187:00 amRNSTrading Statement
20th Sep 20187:00 amRNSResult of AGM
4th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Aug 20187:00 amRNSDirector/PDMR Shareholding
31st Jul 20187:00 amRNSDirector/PDMR Shareholding
10th Jul 20188:00 amRNSDirector/PDMR Shareholding
29th Jun 20184:59 pmRNSPDMR Shareholding
7th Jun 20187:00 amRNSFinal Results
26th Apr 20182:10 pmRNSPDMR Change
25th Apr 20187:00 amRNSDirector/PDMR Shareholding
20th Apr 201812:15 pmRNSPDMR Change
11th Apr 201811:36 amRNSHolding(s) in Company
11th Apr 20187:00 amRNSAppointment of Chief Executive
4th Apr 20187:00 amRNSReceipt of $4.0m Order/Trading Update
29th Mar 20187:00 amRNSDirectorate Change
9th Mar 20187:00 amRNSNew Contract Award
13th Feb 20187:00 amRNSNew Contract Award
4th Dec 20177:00 amRNSContract
30th Nov 20177:00 amRNSNew Contract Award
27th Nov 20177:00 amRNSHalf-year Report
6th Nov 20171:58 pmRNSTrading Update
26th Oct 20177:00 amRNSShare Award
5th Oct 20177:00 amRNSTrading Statement
13th Sep 20173:30 pmRNSResult of AGM
13th Sep 20177:00 amRNSDirectorate Change
25th Aug 20177:00 amRNSIssue of Convertible Loan Notes
1st Aug 20179:07 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSShare Incentive Plan & Issue of Equity
18th Jul 20177:00 amRNSDirector/PDMR Shareholding & TVR
13th Jun 20177:00 amRNSCollaborations with VMWare and Imagination
7th Jun 201712:06 pmRNSHolding(s) in Company
7th Jun 201712:01 pmRNSHolding(s) in Company
7th Jun 20177:00 amRNSFinal Results
6th Jun 20177:00 amRNSLaunch of MyIDaaS
25th May 20177:00 amRNSSchedule 2(g) Disclosure
23rd May 20177:00 amRNSAppointment of Chief Sales Officer
17th May 20177:00 amRNSNon-Executive Director Appointment
9th May 20177:00 amRNSContract Win
8th May 20173:45 pmRNSShare Incentive Plan
8th May 20177:00 amRNSIntercede announces Secure Login for WordPress
5th Apr 20177:00 amRNSTrading Update
31st Mar 20177:00 amRNSListing of Convertible Loan Notes
20th Mar 20177:00 amRNSAppointment of VP, US Gov't & Enterprise Sales
15th Mar 20173:03 pmRNSShare Incentive Plan
9th Mar 20177:00 amRNSAppointment of Adviser
3rd Mar 20177:00 amRNSTrading Update
27th Jan 201712:15 pmRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.